Erectile%20dysfunction Patient Education

Patient Education

Patient and Partner Education

Some men may only need reassurance that decline in sexual function is due to aging, medication, or chronic illnesses and is not necessarily a sign of serious illness
- They may refuse treatment

Education and reassurance may help in preventing further erectile failure due to the above causes
Discuss with patient and partner (if possible) the important treatment options and their associated risks and benefits
Cultural, religious, and economic factors should be taken into consideration
The choice of treatment should be decided together by physician, patient, and partner

Lifestyle Modification

Modifying possible risk factors may be helpful
- Resolving partner relationship issues
- Smoking cessation
- Reduce alcohol/drug abuse
- Regular exercise and weight management

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.